No matter how cynical the overall market is, Gain Therapeutics Inc (GANX) performance over the last week is recorded 27.92%

Gain Therapeutics Inc (NASDAQ: GANX) on Friday soared 5.04% from the previous trading day, before settling in for the closing price of $8.80. Within the past 52 weeks, GANX’s price has moved between $2.00 and $6.19.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 131.63%. The company achieved an average annual earnings per share of -7.50%. With a float of $17.84 million, this company’s outstanding shares have now reached $20.46 million.

Gain Therapeutics Inc (GANX) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Gain Therapeutics Inc is 12.78%, while institutional ownership is 7.34%. The most recent insider transaction that took place on Dec 21, was worth 507. In this transaction Chief Executive Officer of this company sold 206 shares at a rate of $2.46, taking the stock ownership to the 5,286 shares. Before that another transaction happened on Dec 07, when Company’s Chief Executive Officer sold 1,820 for $2.50, making the entire transaction worth $4,550. This insider now owns 4,855 shares in total.

Gain Therapeutics Inc (GANX) Recent Fiscal highlights

As on 9/29/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.45) by $0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -7.50% per share during the next fiscal year.

Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators

Gain Therapeutics Inc (GANX) is currently performing well based on its current performance indicators. A quick ratio of 2.30 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1718.64.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.82, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.21 in one year’s time.

Technical Analysis of Gain Therapeutics Inc (GANX)

Looking closely at Gain Therapeutics Inc (NASDAQ: GANX), its last 5-days average volume was 0.63 million, which is a jump from its year-to-date volume of 0.21 million. As of the previous 9 days, the stock’s Stochastic %D was 73.91%. Additionally, its Average True Range was 0.40.

During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 91.29%, which indicates a significant increase from 86.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.84% in the past 14 days, which was lower than the 78.49% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.25, while its 200-day Moving Average is $3.73. However, in the short run, Gain Therapeutics Inc’s stock first resistance to watch stands at $5.26. Second resistance stands at $5.47. The third major resistance level sits at $5.65. If the price goes on to break the first support level at $4.87, it is likely to go to the next support level at $4.69. Now, if the price goes above the second support level, the third support stands at $4.48.

Gain Therapeutics Inc (NASDAQ: GANX) Key Stats

Market capitalization of the company is 103.12 million based on 12,910K outstanding shares. Right now, sales total 140 K and income totals -17,590 K. The company made 0 K in profit during its latest quarter, and -7,690 K in sales during its previous quarter.